Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CHEK vs PHG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PHG Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

PHG Overall Winner 6-Pillar Tally: CHEK 0 – 6 PHG Matrix Metrics: CHEK 1 – 9 PHG

As of Nov 20, 2026, Koninklijke Philips N.V. (PHG) is the stronger overall head-to-head candidate over Check-Cap Ltd. (CHEK) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CHEK carries a Unified Composite Score of 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin), whereas PHG carries 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin).

  • Composite vs. Pillar Nuance: While CHEK currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. PHG 40.3/100 SELL), PHG captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.8% vs. 0.0% operating margin) and revenue trajectory (+2.1% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CHEK vs PHG
CHEK NASDAQ
Check-Cap Ltd.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$1.61
+1.9% 1D
Market Cap $9.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.94β · 179% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.0 · SMA20: $1.52 · SMA50: $1.80
PHG NYSE Head-to-Head Winner
Koninklijke Philips N.V.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$28.61
-2.19% 1D
Market Cap $28.6B
TTM Revenue $17.8B
Forward P/E 14.0x
Beta / 30D Vol 0.71β · 38% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 15.0 Fund 39.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.0% over 20 days), RSI 51
RSI-14: 51.0 · SMA20: $29.08 · SMA50: $26.59

6-Pillar Scorecard Institutional Category Breakdown (CHEK 0 – 6 PHG)

Columns: Metric · CHEK · PHG
1. Valuation Multiples PHG
Forward P/E N/M 14.0x
Trailing P/E N/M 25.4x
PEG Ratio N/M 0.90x
EV / Revenue N/M 1.9x
2. Growth & Scale PHG
Revenue Growth (YoY) +0.0% +2.1%
Earnings Growth (YoY) +0.0% -85.4%
TTM Revenue (USD) N/A $17.8B
Market Cap $9.2M $28.6B
3. Profitability & Quality PHG
Gross Margin N/A 46.4%
Operating Margin 0.0% 8.8%
Net Profit Margin 0.0% 5.4%
Return on Equity (ROE) -226.2% 8.6%
4. Balance Sheet & Cash Flow PHG
Cash Generation (TTM) N/A $1.82B
Cash Flow Margin N/A 10.3%
Net Cash / Leverage -226.2% ROE $5.39B Net Debt (0.70x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PHG
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 111.5% (51st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat PHG
OpEx & R&D Intensity N/A 37.6% of Rev ($6.68B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CHEK (1) vs PHG (9)
Institutional Metric CHEK PHG Criterion Row Edge
Market Capitalization
Scale
$9.2M $28.6B Larger Scale PHG
Trailing P/E Ratio
Valuation
N/M 25.4x Lower Multiple PHG
Forward P/E Ratio
Valuation
N/M 14.0x Lower Multiple PHG
Revenue Growth (YoY)
Growth
+0.0% +2.1% Higher Growth PHG
Operating Margin (TTM)
Profitability
0.0% 8.8% Higher Margin PHG
Net Profit Margin
Profitability
0.0% 5.4% Higher Margin PHG
Return on Equity (ROE)
Capital Efficiency
-226.2% 8.6% Higher ROE PHG
52-Week Range Position
Momentum
41% ($1–$3) 51% ($24–$33) Stronger Trend PHG
Beta / 30D Volatility
Risk Regime
0.94β · 179% Vol 0.71β · 38% Vol Lower Realized Risk PHG
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite CHEK
Trailing 12M Revenue (USD)
Operating Scale
N/A $17.8B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 46.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.90x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (-226.2% ROE) $1.82B ($5.39B Net Debt (0.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CHEK +7.3 pp
CHEK: +11.03% · PHG: +3.73%
3M Horizon CHEK +7.3 pp
CHEK: +11.03% · PHG: +3.73%
6M Horizon CHEK +7.3 pp
CHEK: +11.03% · PHG: +3.73%
1Y Horizon CHEK +7.3 pp
CHEK: +11.03% · PHG: +3.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CHEK vs PHG. Trailing 12-month operating profitability (CHEK 0.0% vs PHG 8.8%) and valuation multiples (CHEK N/M vs PHG 14.0x Forward P/E) are benchmarked directly in Pillar 4 below.

CHEK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-226.2% · N/M
PHG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$17.8B
Gross Margin46.4%
Op. Margin8.8%
ROE / Fwd P/E8.6% · 14.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CHEK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CHEK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PHG SURGE
12d in phase · OBV DISTRIBUTION
Current IV 111.5%
IV Percentile 51st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PHG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CHEK Moat Profile Cyclical / Execution-Driven Positioning
X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator
Competes within the X-Ray Apparatus & Tubes & Related Irradiation Apparatus value chain with $9.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PHG Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $28.6B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($6.68B)
90D Engineering Disclosures 0 Published

Investor FAQ CHEK vs PHG Key Questions & Quantitative Answers

As of Nov 20, 2026, Koninklijke Philips N.V. (PHG) is the stronger overall head-to-head candidate over Check-Cap Ltd. (CHEK) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CHEK carries a Unified Composite Score of 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin), whereas PHG carries 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin). Composite vs. Pillar Nuance: While CHEK currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. PHG 40.3/100 SELL), PHG captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.8% vs. 0.0% operating margin) and revenue trajectory (+2.1% vs. +0.0% YoY).

PHG leads the Growth & Scale pillar: CHEK posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PHG at +2.1% YoY revenue growth and -85.4% YoY earnings growth on $17.8B TTM revenue (46.4% gross margin, 8.8% operating margin). On trailing 12-month operating scale, CHEK generates N/A in USD-normalized revenue versus $17.8B for PHG. In operating R&D and SG&A reinvestment, CHEK deploys N/A (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($6.68B) (0 disclosures) for PHG.

PHG screens cheaper on headline valuation multiples. CHEK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PHG trades at 14.0x Forward P/E, 25.4x Trailing P/E, 0.90x PEG, and 1.9x EV/Revenue (10.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CHEK (-226.2% ROE) versus PHG (8.6% ROE) capital efficiency.

In options market volatility and institutional positioning, CHEK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 179% Vol realized risk). By comparison, PHG carries 111.5% implied volatility (51st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.71β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.